Alembic Pharma Receives FDA Approval for Generic Ophthalmic Solution, Estimated Market Size at $61 Million

Alembic Pharmaceuticals has received FDA approval for its generic Travoprost Ophthalmic Solution, equivalent to Sandoz's Travatan Z. The solution is used to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The product has an estimated market size of $61 million for the twelve months ending September 2025.